Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Dabigatran/therapeutic use"'
Autor:
Michael Metze, Christian Pfrepper, Tristan Klöter, Stephan Stöbe, Roland Siegemund, Thomas Siegemund, Elvira Edel, Ulrich Laufs, Sirak Petros
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 4, Pp 610-618 (2020)
Abstract Background The residual antithrombotic activity 12 hours after intake of direct oral anticoagulants (DOACs) is of clinical relevance in the setting of bleeding or urgent surgery. Objective To evaluate the effects of DOACs on thrombin generat
Externí odkaz:
https://doaj.org/article/0b75fd2f634648949da32d83eb8b5647
Autor:
Maxim Grymonprez, Mirko Petrovic, Tine L De Backer, M Arfan Ikram, Stephane Steurbaut, Lies Lahousse
Publikováno v:
AGE AND AGEING
Age and Ageing, 52(3):afad038. Oxford University Press
Age and Ageing, 52(3):afad038. Oxford University Press
Background Atrial fibrillation (AF) is associated with cognitive decline, with anticoagulated subjects potentially having a reduced risk compared with non-anticoagulated subjects. However, whether non-vitamin K antagonist oral anticoagulants (NOACs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::149f6a7df371b3dc9327b3f69ad0721d
https://hdl.handle.net/20.500.14017/ba31f320-24d9-4bd5-8fac-78410b796659
https://hdl.handle.net/20.500.14017/ba31f320-24d9-4bd5-8fac-78410b796659
Autor:
Amiee Kang, Xuemei Luo, Jenny Jiang, Gregory Y.H. Lip, Jack Mardekian, Steven Deitelzweig, Huseyin Yuce, Lisa Rosenblatt, Amol D Dhamane, Allison Keshishian, Christian Klem
Publikováno v:
Deitelzweig, S, Keshishian, A, Kang, A, Dhamane, A D, Luo, X, Klem, C, Rosenblatt, L, Mardekian, J, Jiang, J, Yuce, H & Lip, G Y H 2021, ' Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity ', Advances in Therapy, vol. 38, no. 6, pp. 3166-3184 . https://doi.org/10.1007/s12325-021-01724-8
Advances in Therapy
Advances in Therapy
Introduction Non-valvular atrial fibrillation (NVAF) is often accompanied by multiple comorbid conditions, which increase the associated risks and complexity of patient management. This study evaluated the risk of stroke/systemic embolism (SE) and ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fef092ea8a98ade7bc65905d92f9537e
https://doi.org/10.1007/s12325-021-01724-8
https://doi.org/10.1007/s12325-021-01724-8
Autor:
Lars Hvilsted Rasmussen, Steen Dalby Kristensen, Kurt Huber, Fabrizio Ricci, Gregory Y.H. Lip, João Morais, Dirk Sibbing, Agneta Siegbahn, Freek W.A. Verheugt, Raffaele De Caterina, Jørgen Jespersen, Sigrun Halvorsen, Felicita Andreotti, Jean-Philippe Collet, Colin Baigent, Robert F. Storey, Harald Arnesen, Jeffrey I. Weitz, Lars Wallentin, Steen Elkjær Husted, Fedor Bachmann, Jurriën M. ten Berg
Publikováno v:
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Collet, J-P, Halvorsen, S, Huber, K, Jespersen, J, Kristensen, S D, Lip, G Y H, Morais, J, Rasmussen, L H, Ricci, F, Sibbing, D, Siegbahn, A, Storey, R F, Ten Berg, J, Verheugt, F W A & Weitz, J I 2016, ' Oral anticoagulants in coronary heart disease (Section IV) : Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 115, no. 4, pp. 685-711 . https://doi.org/10.1160/TH15-09-0703
Thrombosis and Haemostasis, 115, 4, pp. 685-711
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Collet, J-P, Halvorsen, S, Huber, K, Jespersen, J, Dalby Kristensen, S, Lip, G Y H, Morais, J, Rasmussen, L H, Ricci, F, Sibbing, D, Siegbahn, A, Storey, R F, Ten Berg, J, Verheugt, F W A & Weitz, J I 2016, ' Oral anticoagulants in coronary heart disease (Section IV) : Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 115, no. 4, pp. 685-711 . https://doi.org/10.1160/TH15-09-0703
Thrombosis and Haemostasis, 115, 685-711
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Collet, J-P, Halvorsen, S, Huber, K, Jespersen, J, Kristensen, S D, Lip, G Y H, Morais, J, Rasmussen, L H, Ricci, F, Sibbing, D, Siegbahn, A, Storey, R F, Ten Berg, J, Verheugt, F W A & Weitz, J I 2016, ' Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 115, no. 4, pp. 685-711 . https://doi.org/10.1160/TH15-09-0703
Thrombosis and Haemostasis, 115, 4, pp. 685-711
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Collet, J-P, Halvorsen, S, Huber, K, Jespersen, J, Dalby Kristensen, S, Lip, G Y H, Morais, J, Rasmussen, L H, Ricci, F, Sibbing, D, Siegbahn, A, Storey, R F, Ten Berg, J, Verheugt, F W A & Weitz, J I 2016, ' Oral anticoagulants in coronary heart disease (Section IV) : Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 115, no. 4, pp. 685-711 . https://doi.org/10.1160/TH15-09-0703
Thrombosis and Haemostasis, 115, 685-711
De Caterina, R, Husted, S, Wallentin, L, Andreotti, F, Arnesen, H, Bachmann, F, Baigent, C, Collet, J-P, Halvorsen, S, Huber, K, Jespersen, J, Kristensen, S D, Lip, G Y H, Morais, J, Rasmussen, L H, Ricci, F, Sibbing, D, Siegbahn, A, Storey, R F, Ten Berg, J, Verheugt, F W A & Weitz, J I 2016, ' Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease ', Thrombosis and Haemostasis, vol. 115, no. 4, pp. 685-711 . https://doi.org/10.1160/TH15-09-0703
SummaryUntil recently, vitamin K antagonists (VKAs) were the only available oral anticoagulants evaluated for long-term treatment of patients with coronary heart disease (CHD), particularly after an acute coronary syndrome (ACS). Despite efficacy in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2df839339f412ec880dd78b90f94fcce
https://doi.org/10.1160/th15-09-0703
https://doi.org/10.1160/th15-09-0703
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Catarina Pereira, Daniel Caldeira, António Vaz-Carneiro, João Costa, F Fiorentino, Miguel Gouveia, Luís dos Santos Pinheiro, Mónica Inês, Margarida Borges
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Revista Portuguesa de Cardiologia, Vol 34, Iss 12, Pp 723-737 (2015)
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Revista Portuguesa de Cardiologia, Vol 34, Iss 12, Pp 723-737 (2015)
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
© 2015 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os direitos reservados
Introduction and Objectives: Recently, three novel non-vitamin K antagonist oral anticoagulants received approval for reimbursement
Introduction and Objectives: Recently, three novel non-vitamin K antagonist oral anticoagulants received approval for reimbursement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d4313c14b44adc8f64f4d3337d5f7cc
https://hdl.handle.net/10451/32557
https://hdl.handle.net/10451/32557